FDA 483 - Lornamead Inc. - January 21, 2026

LPNA Group Inc. DBA Lornamead Products was inspected and cited for significant deficiencies across its quality system. Observations included failures to properly record and justify deviations in laboratory testing, inadequate annual product review procedures, and deficient complaint handling processes. These issues indicate a lack of robust quality control and oversight in drug product manufacturing and release.